Last Update 16 Dec 25

Fair value Decreased 0.17%

STMN: Improving U.S. Momentum Will Likely Drive Renewed Optimism And Upside

The analyst price target for Straumann Holding has been modestly increased to CHF 112.24 from CHF 112.43, as analysts factor in improving investor sentiment, gradually better operational momentum in the U.S., and a slightly higher future earnings multiple despite trimmed growth and margin expectations.

Analyst Commentary

Recent research updates on Straumann Holding present a mixed but gradually improving picture, with several bullish analysts highlighting better sentiment and operational progress, while more cautious voices point to lingering earnings and valuation risks.

Bullish Takeaways

Bullish analysts see a notable improvement in investor sentiment following the latest quarterly update, arguing that the stock now faces fewer immediate negative catalysts.
Some expect gradually improving operational momentum in the U.S. to support a reacceleration of top line growth, which could justify a higher earnings multiple over time.
Upgrades to Buy and Neutral ratings from previously more cautious stances suggest that execution risks are seen as more manageable, narrowing the perceived downside skew in the valuation.
Raising price targets into the low CHF 100s is framed as recognition that Straumann can still deliver attractive medium term growth despite trimmed margin expectations.

Bearish Takeaways

Bearish analysts continue to argue that the current share price embeds an overly optimistic recovery path, particularly given slower than previously expected improvement in the U.S. market.
Downward revisions to price targets, including cuts into the CHF 80 range, reflect concerns that earnings growth may lag earlier forecasts, limiting upside to the valuation.
Reduced growth and margin estimates, especially tied to a shallower U.S. recovery, raise questions about Straumann's ability to consistently expand profitability in the near term.
The persistence of Sell and downgraded ratings underscores worries that consensus expectations remain vulnerable to further negative estimate revisions if execution falls short.

What's in the News

Straumann Holding AG scheduled an Analyst and Investor Day, signaling upcoming updates on strategy, growth priorities, and financial outlook for the Group (company event filing).
Straumann Group and Smartee Denti Technology entered a strategic partnership to jointly develop a next generation orthodontics platform and co innovate in clear aligner technologies, including a single digit equity investment by Smartee (company announcement).
Straumann Group announced new strategic partnerships to transform its orthodontics business and unlock the full potential of its ClearCorrect brand, targeting faster innovation, better efficiency, and higher profitability across its clear aligner portfolio (company announcement).

Valuation Changes

Fair Value Estimate: edged down slightly to CHF 112.24 from CHF 112.43, reflecting a marginally more conservative outlook.
Discount Rate: decreased modestly to 4.56 percent from 4.60 percent, indicating a slightly lower implied risk profile.
Revenue Growth: trimmed slightly to 7.95 percent from 8.07 percent, suggesting a marginally softer top line trajectory.
Net Profit Margin: reduced slightly to 20.95 percent from 21.32 percent, pointing to a modestly weaker profitability assumption.
Future P/E: increased slightly to 30.0x from 29.5x, signaling a small uplift in the valuation multiple applied to forward earnings.

Expansion in emerging markets and digital dentistry drives revenue growth, pricing power, and recurring high-margin income.
Diversified manufacturing, products, and local market strategies enhance resilience and position Straumann for long-term above-market growth.
Currency headwinds, tariff risks, price competition in China, underperformance in orthodontics, and sustained high costs threaten margins, earnings growth, and long-term financial targets.

Catalysts

About Straumann Holding

Provides tooth replacement and orthodontic solutions worldwide.What are the underlying business or industry changes driving this perspective?

Strong revenue and earnings growth in Asia-Pacific (particularly China) and Latin America is likely to accelerate as local manufacturing capacity and clinical training investments come online, enabling Straumann to capture a larger share of an expanding addressable market driven by demographic change and rising wealth in emerging economies. (Impacts: revenue, operating margin, EPS)
New product launches such as iEXCEL and digital platforms like SIRIOS and AXS are gaining rapid market share, enhancing Straumann's pricing power in the premium segment and creating potential for higher average selling prices and improved gross margins as adoption increases. (Impacts: revenue growth, gross margin, EBIT margin)
Ongoing expansion in digital dentistry, evidenced by double-digit growth in intraoral scanners and 3D printing solutions, is positioning Straumann to benefit from structural industry shifts toward integrated digital workflows, which should drive recurring higher-margin revenues and operating leverage over time. (Impacts: recurring revenues, net margins, long-term earnings)
Localized manufacturing and regulatory readiness in China, coupled with a multi-brand, multi-price approach, provide a competitive edge as government initiatives improve implant affordability and access-creating a sustainable platform for both volume growth and resilience to potential future price regulation. (Impacts: volume growth, operating income, risk mitigation)
Global population aging and increased oral health awareness continue to drive demand for dental implants and aesthetic procedures; Straumann's diversified global footprint and ongoing investments in education and capacity are likely to enable above-market growth, supporting sustained increases in both top-line and bottom-line performance. (Impacts: long-term revenue growth, margin expansion, EPS growth)

Straumann Holding Earnings and Revenue Growth

Straumann Holding Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Straumann Holding's revenue will grow by 9.1% annually over the next 3 years.
Analysts assume that profit margins will increase from 16.6% today to 21.2% in 3 years time.
Analysts expect earnings to reach CHF 712.0 million (and earnings per share of CHF 4.51) by about September 2028, up from CHF 428.0 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as CHF563.9 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 29.8x on those 2028 earnings, down from 34.6x today. This future PE is lower than the current PE for the GB Medical Equipment industry at 34.6x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 4.5%, as per the Simply Wall St company report.

Straumann Holding Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Ongoing exposure to adverse currency movements (especially Swiss franc strength and weakness in emerging market currencies) has already materially compressed both top-line revenue growth and EBIT margins, and is expected to remain a persistent headwind, limiting earnings growth and potentially decreasing net margins further.
Heightened global trade tensions, including newly imposed and potentially escalating tariffs (particularly U.S.-Brazil and U.S.-Switzerland) could lead to structurally higher costs, squeeze gross and operating margins, and create greater volatility in manufacturing footprint efficiency, thus reducing long-term profitability.
Intensifying price competition in China, tied to uncertain outlooks for VBP (volume-based procurement), could drive pricing pressure and margin erosion; if VBP 2.0 or future cycles involve additional price cuts, this could significantly lower ASPs and limit Straumann's ability to grow revenue in one of its key growth markets.
The orthodontics segment, which was previously a pillar of long-term growth projections, is currently underperforming against management's earlier expectations; weaker-than-planned growth in clear aligners could structurally reduce the company's overall long-term revenue growth profile and impair its ability to reach 2030 targets.
Continuing investment requirements in manufacturing expansion, digital transformation, and innovation are resulting in sustained high CapEx and operating costs, with recent declines in free cash flow; if revenue growth fails to offset these costs due to external headwinds or internal execution risks, net margins and earnings could be pressured over the long term.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CHF117.0 for Straumann Holding based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF145.0, and the most bearish reporting a price target of just CHF85.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be CHF3.4 billion, earnings will come to CHF712.0 million, and it would be trading on a PE ratio of 29.8x, assuming you use a discount rate of 4.5%.
Given the current share price of CHF92.94, the analyst price target of CHF117.0 is 20.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Straumann Holding?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

STMN: Future Performance Will Depend On U S Operational Recovery And Margin Stability